1-5 of 5
Inger S. Nijhof, MD
Close
Sort by
Journal Articles

Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All- Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab

Inger S. Nijhof, MD, Henk M. Lokhorst, MDPhD, Berris van Kessel, Richard W.J. Groen, PhD, Anton C. Martens, PhD, Parul Doshi, PhD, Saskia K. Klein, MDPhD, Tuna Mutis, MDPhD, Kate Sasser, Niels W.C.J. van de Donk, MDPhD
Journal: Blood
Blood (2014) 124 (21): 2096.
https://doi.org/10.1182/blood.V124.21.2096.2096
Published: 2014
Journal Articles

CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients

Inger S. Nijhof, MD, Willy A. Noort, PhD, Jeroen Lammerts van Bueren, PhD, Berris van Kessel, Joost M. Bakker, PhD, Paul W.H.I. Parren, PhD, Richard W.J. Groen, PhD, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD, Anton Martens, PhD
Journal: Blood
Blood (2013) 122 (21): 277.
https://doi.org/10.1182/blood.V122.21.277.277
Published: 2013
Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 287.
https://doi.org/10.1182/blood.V122.21.287.287
Published: 2013
Journal Articles

Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients

Inger S. Nijhof, MD, Jeroen Lammerts van Bueren, Berris van Kessel, Michel de Weers, Joost M Bakker, PhD, Paul W. H. I. Parren, PhD, Henk Lokhorst, MD, PhD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2012) 120 (21): 4988.
https://doi.org/10.1182/blood.V120.21.4988.4988
Published: 2012
Journal Articles

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Inger S. Nijhof, MD, Michel de Weers, PhD, Pascale Andre, PhD, Berris van Kessel, Henk M. Lokhorst, MD, Paul W.H.I. Parren, PhD, Yannis Morel, PhD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2011) 118 (21): 1865.
https://doi.org/10.1182/blood.V118.21.1865.1865
Published: 2011